A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense
oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients
with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.